🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

29 results for “conventional” Clear

  1. AG-120/S95031 250mg film-coated tablet, Ivosidenib-matched Placebo Tablets

    The George Institute

    Locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 or 2 systemic treatment regimens

    phase 3 small molecule active

    1 trial

  2. Conventional medical treatment

    Lxo Ireland Designated Activity Company

    Coronary Atherosclerosis and Other Heart Disease

    phase 3 small molecule completed

    1 trial

  3. Conventional sound generator (SG)

    Camp4 Therapeutics Corp

    Subjective Tinnitus

    phase 3 other completed

    1 trial

  4. Grafalon 20 mg/ml concentrato per soluzione per infusione

    The George Institute

    To analyze whether the anti-rejection treatment of borderline lesions can modify the expression and klotho levels, as well as proinflammatory cytokines that regulate klotho expression at both years post-transplant., Know in a controlled and randomized clinical trial, carried out in low-risk patients immunological and stable renal function, if the treatment of BL lesions, detected in the third month post-transplant, with rabbit polyclonal antilymphocytic globulin prevents or slows the progression of chronic histological lesions of the graft (FIAT) and the deterioration of its function compared to clinical follow-up conventional, after two years of post-transplant follow-up.

    phase 3 small molecule active

    1 trial

  5. Solution de chlorure de sodium à 0,9%, Allogeneic umbilical cord derived MSC (thawed and washed)

    Pari Pharma GmbH

    Adult Patients kidney transplant recipients who have developed chronic humoral rejection, diagnosed through a kidney biopsy (Banff 2017 Classification), resistant to conventional treatment (3 injections at one-month intervals of 2g/kg of IVIG)

    phase 3 small molecule active

    1 trial

  6. XEOMIN 200 unités, poudre pour solution injectable, Placebo of Xeomin 200 U

    Pari Pharma GmbH

    Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery)

    phase 3 small molecule active

    1 trial

  7. A Phase I/II open label study to assess safety and preliminary evidence of a therapeutic effect of Azeliragon combined with conventional concurrent radiation and temozolomide in patients with newly diagnosed glioblastoma.

    Lacuna Pharma Pty Ltd

    Glioblastoma

    phase 2 other active

    1 trial

  8. ACETYLCYSTEINE , DEXAMETHASONE , DIPHENHYDRAMINE , GLUCOSE

    Inhibrx Biosciences

    Unresectable or metastatic conventional chondrosarcoma

    phase 2 small molecule active

    1 trial

  9. Anterior lamellar nanostructured artificial human cornea.

    Lxo Ireland Designated Activity Company

    Severe Trophic Corneal Ulcers Refractory to Conventional Treatment

    phase 2 small molecule completed

    1 trial

  10. CASPONEB - Phase II safety lead-in randomized blind placebo controlled clinical trial : efficacy and safety of caspofungin aerosols for the curative treatment of Pneumocystis pneumonia in adjunction of conventional systemic antifungal therapy

    Tour Hekla

    Pneumocystis pneumonia

    phase 2 other active

    1 trial

  11. Conventional Roux-en-Y Gastrojejunostomy

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 other active

    1 trial

  12. Conventional therapy

    Chinese Academy of Sciences

    Decompensated Cirrhosis

    phase 2 mab active

    1 trial

  13. Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.

    Lxo Ireland Designated Activity Company

    Graft Versus Host Disease

    phase 2 other completed

    1 trial

  14. INBRX-109

    Inhibrx Biosciences

    Conventional Chondrosarcoma

    phase 2 small molecule active

    1 trial

  15. conventional therapy plus low dose hUC-MSCs treatment

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Liver Cirrhosis

    phase 2 mab completed

    1 trial

  16. A dose-finding Phase I study of F8IL10 intra-articular treatment in Rheumatoid Arthritis

    Philogen S.p.A.

    Patients with Rheumatoid Arthritis (RA) who, despite treatment with stable doses (for at least 3 months) of disease-modifying antirheumatic drugs (DMARDs, conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable for intra-articular (IA) injection in a knee, shoulder, ankle, wrist or elbow.

    phase 1 other active

    1 trial

  17. AN OPEN-LABEL, RANDOMIZED, SINGLE DOSE, TWO-STAGE CROSSOVER ADAPTIVE BIOEQUIVALENCE STUDY OF TRIAMCINOLONE ACETONIDE 40 MG/ML STERILE INJECTABLE SUSPENSION (Test product–Lisapharma S.p.A) VERSUS KENACORT® 40 MG/ML SUSPENSION (Reference product – Bristol Myers Squibb) AFTER INTRAMUSCULAR ADMINISTRATION TO HEALTHY VOLUNTEERS

    Lacuna Pharma Pty Ltd

    Intramuscular administration of triamcinolone acetonide Lisapharma (Injectable suspension of triamcinolone acetonide) is indicated for systemic corticosteroid therapy in morbid conditions such as allergic syndrome (to control severe or debilitating conditions not treatable in a conventional way), dermatoses, generalized rheumatoid arthritis and other connective tissue diseases.

    phase 1 other active

    1 trial

  18. clinical trial to determine the feasibility and safety of the mesenchymal stem cells use in women over 50 years of age with urinary incontinencee

    The George Institute

    Stress or mixed urinary incontinence in women over 50 years of age not responding to conventional treatments

    phase 1 other active

    1 trial

  19. Conventional therapy + S (+)-Ketamine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    S-ketamine

    approved small molecule active

    1 trial

  20. conventional dose epinephrine

    Hospital Authority, Hong Kong

    Croup

    approved small molecule active

    1 trial

  21. Combination Product: Conventional third-line therapy

    The First People's Hospital of Lianyungang

    Colorectal Cancer (CRC)

    other active

    1 trial

  22. Conventional Artificial Cycle Therapy

    Jian Li

    Infertility, Female

    small molecule active

    1 trial

  23. Conventional second-line therapy

    The First People's Hospital of Lianyungang

    Colorectal Cancer (CRC)

    other active

    1 trial

  24. Conventional third-line therapy

    The First People's Hospital of Lianyungang

    Colorectal Cancer (CRC)

    other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources